Gland Pharma Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/jf05mm3bccpwfg2ciq87fvmy.pdf

Key Takeaways


The Strategic Manufacturing Agreement

Ravi Mitra: "To be fair, without Cenexi, this wouldn't have happened in a way. So that also strengthens our strategic initiative when we acquired Cenexi because otherwise, we couldn't have provided the full best solution for the partner."

CDMO & B2B Performance

SegmentGrowthCommentary
CDMO▲ 20% YoY50% of total revenue; driven by recent product launches and progression of existing commercial programs.
B2B▲ 19% YoYIncreased demand from existing customers, new contract wins, higher volumes, and supply reliability enabling market share expansion.
US▲ 32% YoYRecent CDMO launches plus volume expansion; MVI and Dalbavancin ramping as expected.
Europe & other regulatory▲ 11% YoYIncreasing customer engagement, launch contributions, improving CDMO momentum.
ROW▬ FlatDemand healthy but Saudi Arabia supply disruptions and delayed NUPCO tenders weighed.
Srinivas Sadu: "We looked at opportunity where probably everybody is saying that there's no money in generics, but we're saying, okay, we -- our strength is in manufacturing and quality, why can't we leverage that to offer these services so that they'll be more competitive."

New Collaborations & Pipeline

Srinivas Sadu: "We don't have a clear visibility on the front-end approval status for these products. So it's very difficult to assume the numbers for them. So that's why we're keeping close to our chest how that pans out, but that will be an upside if it pans out well."

Margins & Profitability

MetricQ1 FY27YoY Change
Gross margin65%Favorable product mix, higher CDMO contribution, operational efficiencies, procurement initiatives, yield improvement.
Adjusted EBITDA margin28%Up from 25%; driven by higher CDMO revenue, favorable mix, operating leverage, productivity, cost optimization.
PAT—+47% YoY; sequential decline vs Q4 FY26 due to forex loss vs prior-quarter forex gain.
R&D spend—+16% YoY; focused on complex injectable peptides, depot products, drug delivery, liposomal products.
Cash flow from operations₹318.3 croreStrong operating performance and disciplined working capital management.

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth~20% growth over next 4 years, up from prior 15% CAGRFY27–FY30
Current-year growth15% constant currency growth "clearly achievable"; could exceed 15% if bag line FDA approval lands by August/SeptemberFY27
Strategic agreement revenueRevenue generation anticipated from calendar year 2029; entire portfolio launched by CY30CY29–CY30
Strategic agreement revenue potentialApproximately $9–10 crore once all products commercializedBy CY30
CDMO mix30% CDMO near-term; ~50-50 CDMO/B2B in 2 years; CDMO larger than B2B by CY29Near-term to CY29
EBITDA margin30% near-term; 35% in 3–4 yearsNear-term to FY30–31
Cenexi guidanceNear €20 crore revenue, high single-digit margins for FY27; double-digit EBITDA by year-endFY27
Liposomal product revenueMeaningful contribution expected from FY30; product estimated at $300 crore over next 3 yearsFY30 onward
GLP-1 revenueVery limited over next 3 years; major U.S. volume in FY30–31FY30–31
Complex products contributionMost complex products post-FY29; next growth driver after the 4-year 20% growth periodPost-FY29
Fontenay ampoule lineNew high-capacity line enters production in early 2027; adds ~3 crore ampoules annual capacityEarly 2027
Cenexi growth capexNew block with vial and lyos at BLA, high-speed ampoule line at Fontenay to finish by end of next yearEnd of FY28
NUPCO tendersAward delayed; results expected shortlyUndated

Key Metrics

MetricQ1 FY27
Revenue₹1,800.3 crore, +20% YoY
Adjusted EBITDA₹510.2 crore, adjusted EBITDA margin 28%
Reported EBITDA₹493 crore, EBITDA margin 27%, vs 24% in Q1 FY26
Profit after tax₹317 crore, +47% YoY, PAT margin 18%
Gross margin65%, supported by favorable product mix and CDMO contribution
CDMO revenue₹891.5 crore, +20% YoY, 50% of total revenues
B2B revenue₹908.8 crore, +19% YoY, 50% of total revenues
US revenue₹981 crore, +32% YoY
Europe and other regulatory markets revenue₹448.8 crore, +11% YoY
Rest of world revenue₹303.9 crore, broadly in line with corresponding period last year
India revenue₹66.6 crore
R&D spend₹77.2 crore, ~4% of consolidated revenue, +16% YoY
Forex loss₹3.6 crore, vs forex gain of ₹50.8 crore in Q4 FY26 and ₹3.9 crore in Q1 FY26
Other income₹61.2 crore, primarily interest income
Effective tax rate~27%
Cash and cash equivalents₹3,546.6 crore as of June 30, 2026
Net cash position₹3,293.9 crore
Cash flow from operations₹318.3 crore
Capital expenditure₹113.2 crore in Q1; FY27 planned spend ~₹550 crore
Cenexi revenueEUR 4.8 crore, EBITDA EUR 0.2 crore
US filings and approvals3 ANDAs filed, 7 approvals received, 4 products launched
Strategic manufacturing agreement55 SKUs across 3 sites, revenue potential ~$9–10 crore, revenues expected from CY2029
Constant currency growth15% for Q1 consol; 15% "clearly achievable" for FY27
Growth outlook~20% growth next 4 years with new contract in place
Profit share~9% of revenue this quarter
NDDS projectRevenue potential $2.5–3 crore, timeline '28, commercialize '29